Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of cash, cash equivalents, and restricted cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported within the Unaudited Condensed Consolidated Balance Sheets to “Cash, cash equivalents, and restricted cash at end of period” as reported within the Unaudited Condensed Consolidated Statements of Cash Flows:



In thousands	March 31, 2020		December 31, 2019
Cash and cash equivalents	$	6,917	$	516
Restricted cash included in other assets	32,657		32,529
Total cash, cash equivalents, and restricted cash shown in the Unaudited Condensed Consolidated Statements of Cash Flows	$	39,574	$	33,045

Schedule of earnings per share, basic and diluted reconciliation

The following table sets forth the reconciliations of net income (loss) and weighted average shares used for purposes of calculating the basic and diluted net income (loss) per common share for the periods indicated:



	Three Months Ended
	March 31,
In thousands	2020		2019
Numerator
Net income (loss) – basic	$	74,016	$	(25,674	)
Effect of potentially dilutive securities
Interest on convertible senior notes including amortization of discount, net of tax	5,857		—
Net income (loss) – diluted	$	79,873	$	(25,674	)

Denominator
Weighted average common shares outstanding – basic	494,259		451,720
Effect of potentially dilutive securities
Restricted stock and performance-based equity awards	1,078		—
Convertible senior notes⁽¹⁾	90,853		—
Weighted average common shares outstanding – diluted	586,190		451,720

(1)

For the three months ended March 31, 2020, shares shown under “convertible senior notes” represent the impact over the period of the approximately 90.9 million shares of the Company’s common stock issuable upon full conversion of our convertible senior notes which were issued on June 19, 2019.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following securities could potentially dilute earnings per share in the future, but were excluded from the computation of diluted net income (loss) per share, as their effect would have been antidilutive:



	Three Months Ended
	March 31,
In thousands	2020	2019
Stock appreciation rights	1,528	2,091
Restricted stock and performance-based equity awards	14,007	8,350